eMedicine Specialties > Pediatrics: General Medicine > Hematology

Bernard-Soulier Syndrome

Author: John D Geil, MD, Associate Professor of Pediatrics, Division of Hematology/Oncology, University of Kentucky College of Medicine; Consulting Staff, Department of Pediatric Hematology/Oncology, University of Kentucky Children's Hospital
Contributor Information and Disclosures

Updated: Jun 30, 2009

Introduction

Background

Bernard-Soulier syndrome (BSS) was first described in 1948 as a congenital bleeding disorder characterized by thrombocytopenia and large platelets. The disorder was recognized to be familial and inherited in an autosomal recessive manner. In the 1970s, the molecular defect was shown to involve the absence of a platelet membrane glycoprotein. Bernard-Soulier syndrome is one of a group of hereditary platelet disorders characterized by thrombocytopenia, giant platelets, and a tendency toward bleeding. Other disorders in this category are the May-Hegglin anomaly and gray platelet syndrome.

Peripheral smear of a patient with Bernard-Soulie...

Peripheral smear of a patient with Bernard-Soulier syndrome (BSS) showing giant platelets. These platelets are not counted as platelets in most particle counters.

Peripheral smear of a patient with Bernard-Soulie...

Peripheral smear of a patient with Bernard-Soulier syndrome (BSS) showing giant platelets. These platelets are not counted as platelets in most particle counters.

Pathophysiology

The underlying biochemical defect is the absence or decreased expression of the glycoprotein Ib/IX/V complex on the surface of the platelets.1 This complex is the receptor for von Willebrand factor (vWF), and the result of decreased expression is deficient binding of vWF to the platelet membrane at sites of vascular injury, resulting in defective platelet adhesion. This is demonstrated by the lack of aggregation of platelets in response to ristocetin, an antibiotic that normally causes platelets to aggregate. The end result is the lack of formation of the primary platelet plug and increased bleeding tendency. The cause of the thrombocytopenia is not definitely known, but it is probably related to a decreased platelet life span.

Frequency

United States

This syndrome is rare, with an estimated occurrence of less than 1 case per million population.

Mortality/Morbidity

The severity of bleeding tendency varies. Bleeding can be severe with injury or surgery.

Race

Bernard-Soulier syndrome is a rare disorder described primarily in whites of European ancestry, as well as in the Japanese population. However, prevalence in other ethnic groups is unknown.

Sex

Males and females are affected with equal frequency.

Age

Bleeding due to Bernard-Soulier syndrome may begin in infancy and may continue with varying severity throughout life.

Clinical

History

Symptoms of Bernard-Soulier syndrome (BSS) are consistent with low or dysfunctional platelets and include easy bruising, nosebleeds, mucosal bleeding, menorrhagia, and, occasionally, GI bleeding. The severity of symptoms may widely vary.

Physical

The physical examination findings are consistent with low or dysfunctional platelets and may include increased bruising and mucosal bleeding.

Causes

Bernard-Soulier syndrome is inherited in an autosomal recessive fashion; thus, males and females are affected with equal frequency. Heterozygotes usually have no bleeding manifestations.

More on Bernard-Soulier Syndrome

Overview: Bernard-Soulier Syndrome
Differential Diagnoses & Workup: Bernard-Soulier Syndrome
Treatment & Medication: Bernard-Soulier Syndrome
Follow-up: Bernard-Soulier Syndrome
Multimedia: Bernard-Soulier Syndrome
References

References

  1. Young G, Luban N, White JG. Giant platelet disorders in African-American children misdiagnosed as idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. May-Jun 1999;21(3):231-6. [Medline].

  2. Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med. Dec 2007;131(12):1834-6. [Medline].

  3. Cohn RJ, Sherman GG, Glencross DK. Flow cytometric analysis of platelet surface glycoproteins in the diagnosis of Bernard-Soulier syndrome. Pediatr Hematol Oncol. Jan-Feb 1997;14(1):43-50. [Medline].

  4. Enomoto TM, Thorborg P. Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit Care Clin. Jul 2005;21(3):611-32. [Medline].

  5. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost. Jun 2005;93(6):1027-35. [Medline].

  6. Hacihanefioglu A, Tarkun P, Gonullu E. Use of recombinant factor VIIa in the management and prophylaxis of bleeding episodes in two patients with Bernard-Soulier syndrome. Thromb Res. 2007;120(3):455-7. [Medline].

  7. Jantunen E. Inherited giant platelet disorders. Eur J Haematol. Oct 1994;53(4):191-6. [Medline].

  8. Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol. Nov 2002;76(4):319-27. [Medline].

  9. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood. Jun 15 1998;91(12):4397-418. [Medline][Full Text].

  10. Mhawech P, Saleem A. Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol. Feb 2000;113(2):176-90. [Medline].

  11. Nurden AT. Inherited abnormalities of platelets. Thromb Haemost. Aug 1999;82(2):468-80. [Medline].

  12. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost. Aug 2005;3(8):1773-82. [Medline].

  13. Poon MC, d'Oiron R. Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis. Apr 2000;11 Suppl 1:S55-68. [Medline].

  14. Tefre KL, Ingerslev J, Sorensen B. Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia. Jan 2009;15(1):281-4. [Medline].

  15. Watanabe R, Ishibashi T, Saitoh Y, et al. Bernard-soulier syndrome with a homozygous 13 base pair deletion in the signal peptide-coding region of the platelet glycoprotein Ib(beta) gene. Blood Coagul Fibrinolysis. Jun 2003;14(4):387-94. [Medline].

  16. Zieger B, Jenny A, Tsakiris DA, et al. A large Swiss family with Bernard-Soulier syndrome - Correlation phenotype and genotype. Hamostaseologie. May 2009;29(2):161-7. [Medline].

Further Reading

Keywords

Bernard-Soulier syndrome, BSS, hereditary platelet disorder, bleeding disorder, coagulation disorder, giant platelets, thrombocytopenia, bleeding tendency, May-Hegglin anomaly, gray platelet syndrome, von Willebrand factor, vWF, treatment, diagnosis

Contributor Information and Disclosures

Author

John D Geil, MD, Associate Professor of Pediatrics, Division of Hematology/Oncology, University of Kentucky College of Medicine; Consulting Staff, Department of Pediatric Hematology/Oncology, University of Kentucky Children's Hospital
John D Geil, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, and Society for Neuro-Oncology
Disclosure: Nothing to disclose.

Medical Editor

Gary R Jones, MD, Associate Medical Director, Clinical Development, Berlex Laboratories
Gary R Jones, MD is a member of the following medical societies: American Academy of Pediatrics, American Society of Pediatric Hematology/Oncology, and Western Society for Pediatric Research
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Gary D Crouch, MD, Program Director of Pediatric Hematology-Oncology Fellowship, Department of Pediatrics, Associate Professor, Uniformed Services University of the Health Sciences
Gary D Crouch, MD is a member of the following medical societies: American Academy of Pediatrics and American Society of Hematology
Disclosure: Nothing to disclose.

CME Editor

David Pallares, MD, Clinical Assistant Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Louisville
David Pallares, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology
Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD, King Fahd Professor of Pediatric Oncology, Professor of Pediatrics, Oncology and the Cellular and Molecular Medicine Graduate Program, Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine
Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, and American Society of Pediatric Hematology/Oncology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.